Pfizer inc., Pharmaceutical company

New York, June 29 Pfizer and Moderna vaccines, the first two jabs authorised for emergency use against Covid-19 by the US Food and Drug Administration (FDA), produce immune responses that are both strong and potentially long-lasting, finds a study.While both vaccines performed well in clinical trials, and have been widely credited with reducing disease, concerns remained over how long immunity induced by the mRNA-based shots will last.The study, led by researchers from the Washington University School of Medicine in St Louis showed that nearly four months after the first dose people who received the Pfizer vaccine still had so-called germinal centers in their lymph nodes churning out immune cells directed against SARS-CoV-2, the virus that causes Covid-19.The team found that even three weeks after the first dose, all 14 participants had formed germinal centers with B cells producing antibodies that target a key SARS-CoV-2 protein. The response expanded greatly after the booster shot and then stayed high.Even 15 weeks after the first dose, eight of 10 people still had detectable germinal centers containing B cells targeting the virus."Germinal centers are the key to a persistent, protective immune response," said Ali Ellebedy, Associate Professor of pathology and immunology, of medicine and of molecular microbiology."Germinal centers are where our immune memories are formed. And the longer we have a germinal center, the stronger and more durable our immunity will be because there's a fierce selection process happening there, and only the best immune cells survive," Ellebedy added.Moreover, vaccination led to high levels of neutralising antibodies effective against three variants of the virus, including the Beta variant from South Africa that has shown some resistance to vaccines.Vaccination also induced stronger antibody responses in people who had recovered from SARS-CoV-2 infection compared to those who had never been infected. Among people without prior exposure to the virus, antibody levels rose slowly after the first dose and peaked one week after the second.Both Pfizer and Moderna vaccines were created with mRNA technology. Unlike most vaccines, which provide bits of viral or bacterial proteins to trigger an immune response, mRNA-based vaccines provide instructions for the body to build and release foreign proteins, such as the spike protein in the case of the SARS-CoV-2 virus.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Pfizer Inc.FOLLOW

Pfizer inc., Latest News

Canberra, July 7 Austral under the age of 40 could become eligible for the Pfizer or Moderna coronavirus ... ...

Tel Aviv, July 6 Israel said on Tuesday that it was sending about 700,000 doses of the Pfizer ... ...

Israel has signed a deal with South Korea to ship 7,00,000 doses of the Pfizer-BioNTech coronavirus vaccine that are soon to expire to get the same amount of shots back later in the fall, Israeli Prime Minister Naftali Bennett said on Tuesday. ...

The Indian drug regulator has urged Pfizer twice in writing to apply for emergency use authorization for its COVID-19 vaccine so that the application is processed well in time but Pfizer has not applied for the license yet, said sources on Tuesday. ...

Germany on Friday recommended that people mix AstraZeneca COVID vaccines with Pfizer or Moderna to enhance immune responses against coronavirus and shorten the interval period between the two shots. ...

Sydney, July 2 The government of Australia's New South Wales (NSW) announced the expansion of Covid-19 vaccine facilities, ... ...

London, June 29 Taking the first dose of Pfizer Covid vaccine and then AstraZeneca for the second can ... ...

New York, June 29 Pfizer and Moderna vaccines, the first two jabs authorised for emergency use against Covid-19 ... ...